Physician profile
Noah M Hahn
NPI 1376582197
$133,043.01
in general payments reported to CMS, 2019-2025
22 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $20K · 2021: $21K · 2022: $25K · 2023: $6,075 · 2024: $5,377 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,638.80 |
| Food and Beverage | $586.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $24,697.24 | 2019 | |
| Merck Sharp & Dohme LLC | $20,291.30 | 2020-2025 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $18,201.02 | 2021-2025 | Imfinzi |
| Pfizer INC. | $16,865.56 | 2020-2025 | |
| Seagen INC. | $14,857.12 | 2019-2023 | Padcev |
| Emd Serono, INC. | $9,735.34 | 2020-2023 | |
| Janssen Global Services, LLC | $6,133.34 | 2020-2021 | |
| Genentech, INC. | $4,258.92 | 2019 | |
| Astellas Pharma Global Development | $4,155.00 | 2022-2023 | Padcev |
| Glaxosmithkline, LLC. | $3,308.37 | 2019 | |
| Astrazeneca Uk Limited | $2,857.10 | 2023-2025 | Imfinzi |
| Boehringer Ingelheim International Gmbh | $2,755.00 | 2020 | |
| Verity Pharmaceuticals INC. | $2,400.00 | 2022 | |
| Astellas Pharma US INC | $2,238.14 | 2025 | Padcev |
| Janssen Biotech, INC. | $114.74 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $92.51 | 2019 | |
| Genentech USA, INC. | $61.45 | 2019 | |
| Gilead Sciences, INC. | $20.86 | 2025 | Trodelvy |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.